Full text is available at the source.
Abstract
Semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events compared to a control group.
- The control group included 896,257 individuals, while the semaglutide cohort consisted of 1,766 patients.
- After adjusting for age, sex, socioeconomic status, and comorbidities, semaglutide treatment resulted in 702 kidney disease events, compared to 1,068 in the control group.
- The hazard ratio for the primary event risk was 0.74, indicating a significant reduction in risk.
- These findings align with a 24% risk reduction reported in the FLOW clinical trial.
- Real-world evidence supports the renoprotective effects of semaglutide in managing renal complications.
Simplified